Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with Mitoxantrone-based reinduction in relapsed/refractory ALL or LL
NCT02535806Phase 2Terminated
- Sponsor
- Children's Mercy Kansas City
- Start
- Jul 2015
- Primary completion
- May 2017
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by Children's Mercy Kansas City. Primary endpoint: Number of Subject With Adverse Events at 36 days. Started Jul 2015; status: terminated.
02
Drugs
bortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT02535806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535806.